Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature – We evaluated the use of chimeric antigen receptor-modified T cells targeting GD2 (GD2-CART) for H3K27M+ diffuse midline glioma (DMG), finding that intravenous administration of…